Feedback / Questions
AVZO-103 - Avenzo Therap
https://www.businesswire.com/news/home/20251124173033/en/Avenzo-Therapeutics-Granted-Fast-Track-Designation-for-AVZO-103-a-Potential-Best-in-Class-Nectin4TROP2-Bispecific-Antibody-Drug-Conjugate-for-the-Treatment-of-Patients-with-Urothelial-Cancer-Previously-Treated-with-Enfortumab-Vedotin
Nov 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next